Why is Gland Pharma falling/rising?

As of 18-Sep, Gland Pharma Ltd's stock price is rising, currently at 2,017.80, reflecting an increase of 30.85 or 1.55%. The stock has shown strong performance today, outperforming its sector by 0.5%. It is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend. Additionally, the delivery volume has increased by 8.19% compared to the 5-day average, suggesting rising investor participation. Over the past week, Gland Pharma has gained 2.66%, and year-to-date, it has returned 12.81%, significantly outperforming the benchmark Sensex, which has only increased by 6.24% during the same period. The company's low debt-to-equity ratio and strong quarterly results, including the highest net sales and profit before tax, further bolster investor confidence.
In the broader market context, Gland Pharma's recent performance stands out as the stock has generated a return of 9.52% over the past year, while the broader market (BSE500) has experienced negative returns of -1.96%. This contrast highlights the stock's resilience despite broader market challenges. However, it is important to note that the company faces risks, including poor long-term growth and a high valuation compared to its peers, which could impact future performance. The stock's relatively high price-to-book value and a PEG ratio of 6.5 suggest that it may be trading at a premium, which could deter some investors in the long run.